Rep. Carolyn Maloney (D-N.Y) on Tuesday asked the FTC to investigate whether AbbVie's pricing and business practices broke the law.

AbbVie Abused Humira’s Orphan Drug Designation, House Panel Says

A U.S. House committee alleged Tuesday that AbbVie gamed the federal orphan drug program to boost profits for its anti-inflammatory drug Humira—by far, the top-selling medicine in the United States.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »